Overview

A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the safety and efficacy of VI-0521 compared to placebo in the treatment of obese adults with obstructive sleep apnea (OSA) and to assess the relative contributions of weight loss on parameters of OSA in these subjects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
VIVUS, Inc.